A six-month interim analysis from a study comparing Xiamen Innovax Biotech’s Cecolin 9 HPV vaccine with Gardasil 9 was presented at an international papillomavirus conference in Athens in October 2026. The company’s announcement did not disclose the analysis’s findings.

Key Takeaways

  • The Phase III study compares the immune response and safety of single-dose Cecolin 9 with Gardasil 9.
  • The multinational study is being conducted in Ghana and the Philippines, with final data expected in 2028.

Cecolin 9 study presentation

Dr. Nana A. Ansah of Ghana’s Navrongo Health Research Centre presented the Month 6 interim analysis of PATH’s Single-dose HPV Immunobridging Study with New Vaccines, known as SHINE I or CVIA 104.

The double-blind, randomized study covers girls aged 9–14 and young women aged 15–20. Because the announcement did not provide the interim results, it does not establish how the two vaccines compared.

Vaccine portfolio and conference

Xiamen Innovax Biotech, also known as IX, said it launched the nine-valent Cecolin 9 vaccine in China in 2025. Its portfolio also includes Cecolin, a bivalent HPV vaccine prequalified by the World Health Organization.

The company participated in the International Papillomavirus Society’s 38th annual conference, held in Athens from October 22 to 25, 2026. It said discussions included vaccine innovation, accessibility and international collaboration.

Next milestone

Final study data are expected in 2028.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.